NCT01165008

Anakinra in Myositis

Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: —
• Sponsor: Karolinska Institutet · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To investigate the effect of the interleukin-1 (IL-1) blocking agent, anakinra, in patients with treatment-resistant inflammatory myopathies. Patients and methods: Fifteen patients with refractory polymyositis (PM), dermatomyositis (DM), or inclusion body myositis (IBM) were treated with 100 mg anakinra subcutaneously per day during 12 months. Outcome measures included myositis disease activity score with improvement defined according to The International Myositis Assessment and Clinical Studies Group (IMACS) and for muscle performance the functional index of myositis (FI). In addition repeat muscle biopsies were performed

Conditions

• Polymyositis
• Dermatomyositis
• Inclusion Body Myositis

Interventions

Type	Name	Description
DRUG	Anakinra

Timeline

• Start date: 2003-09-01
• Completion: 2008-09-01
• First posted: 2010-07-19
• Last updated: 2010-07-19

Locations

1 site across 1 country: Sweden